This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Allergies Antibody Scientist 
Scienmag
MARCH 5, 2021
Scientists at Walter Reed Army Institute of Research, in a collaboration the Duke University, have confirmed that monoclonal antibodies can be an effective tool in the global fight against malaria.
74 
Scienmag
JUNE 29, 2021
Six antibody features help protect pregnant women against placental malaria infections, and could be used to identify women at risk of the disease and related complications Six antibody characteristics could help scientists identify which pregnant women are at risk of placental malaria infections, finds a study published today in eLife.
65
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
AUGUST 12, 2021
A single dose of a monoclonal antibody developed by scientists at the US National Institutes of Health (NIH) has provided protection for people exposed to malaria parasites for up to nine months. The post More malaria hope as antibody protects against infection appeared first on.
64 
Scienmag
FEBRUARY 25, 2021
Research from the California Institute of Technology shows exactly how antibodies stick to and block the Zika virus, which will inform vaccine development Credit: Image courtesy of Shannon Esswein.
52 
Scienmag
JUNE 1, 2021
Army scientists working as part of an international consortium have developed and tested an antibody-based therapy to treat Crimean-Congo hemorrhagic fever virus (CCHFV), which is carried by ticks and kills up to 60 percent of those infected. Their results are published online today in the journal Cell.
57 
Scienmag
APRIL 22, 2021
SARS-CoV-2 can recruit a haem metabolite to evade antibody immunity Researchers have identified another potential target for neutralizing antibodies on the SARS-CoV-2 Spike protein that is masked by metabolites in the blood.
46 
Scienmag
AUGUST 17, 2020
— University of Wisconsin-Madison scientists have discovered that a majority of back-pain patients they tested who were taking opioid painkillers produced anti-opioid antibodies. These antibodies may contribute to some of the negative side effects of long-term opioid use. MADISON, Wis.
50 
Delveinsight
AUGUST 6, 2020
Scientists have already isolated many highly potent neutralizing antibodies from patients who recovered from COVID-19. These antibodies defend a cell from infection by squarely preventing the pathogen’s biological activities. FDA turns back peanut allergy patch of DBV Technologies.
53 
Scienmag
DECEMBER 16, 2020
Scientists at the Ragon Institute of MGH, MIT and Harvard find that neutralizing antibody potency predicts severe or fatal COVID-19. Of particular interest are neutralizing antibodies, which can block the virus from […]. Of particular interest are neutralizing antibodies, which can block the virus from […].
40 
Scienmag
NOVEMBER 2, 2020
2, 2020 – University of Pittsburgh School of Medicine scientists have discovered the fastest way to identify potent, neutralizing human monoclonal antibodies against SARS-CoV-2, the virus that causes COVID-19. Credit: UPMC PITTSBURGH, Nov.
40 
Scienmag
JANUARY 25, 2021
OHSU study has important implications for vaccines, diagnosis of COVID-19 A new study demonstrates that antibodies generated by the novel coronavirus react to other strains of coronavirus and vice versa, according to research published today by scientists from Oregon Health & Science University.
40 
Scienmag
MAY 12, 2021
Scripps Research scientists propose an innovative vaccine approach to protect against a troublesome family of viruses that present a major global health risk LA JOLLA, CA–Scientists at Scripps Research have unveiled a new Ebola virus vaccine design, which they say has several advantages over standard vaccine approaches for Ebola and related viruses (..)
47 
Scienmag
OCTOBER 23, 2020
The technique should help in the design of vaccines against HIV, SARS-CoV-2 and other viruses that cloak their outer proteins with sugars to evade antibodies.
61 
Scienmag
JANUARY 10, 2021
January 11, 2021) – To build better vaccines, scientists want to know more about how our bodies make adequate numbers of effective, durable antibodies against the influenza virus. Credit: Kim Ratliff, Augusta University AUGUSTA, Ga.
59 
The Pharma Data
NOVEMBER 9, 2020
Food and Drug Administration (FDA) today granted Emergency Use Authorization (EUA) for Eli Lilly and Company’s (NYSE: LLY) investigational neutralizing antibody bamlanivimab (LY-CoV555) 700 mg. Bamlanivimab is a recombinant, neutralizing human IgG1 monoclonal antibody (mAb) directed against the spike protein of SARS-CoV-2.
52 
The Pharma Data
JANUARY 26, 2021
. “These exciting results, which replicate positive Phase 2 data in a much larger set of patients, add valuable clinical evidence about the role neutralizing antibodies can play in fighting this pandemic. Lilly’s chief scientific officer and president of Lilly Research Laboratories. have reached record highs.
52 
The Pharma Data
OCTOBER 28, 2020
government to supply 300,000 vials of bamlanivimab (LY-CoV555) 700 mg, an investigational neutralizing antibody, for $375 million. The supply of Lilly’s antibody therapy is expected to increase substantially beginning in Q1 2021, as additional manufacturing resources come online throughout the year. INDIANAPOLIS, Oct.
40 Scienmag
FEBRUARY 22, 2021
Monoclonal antibodies are part of the therapeutic arsenal for eliminating cancer cells. ” But how do these antibodies function within the tumor? Using innovative in vivo imaging approaches, scientists […]. Using innovative in vivo imaging approaches, scientists […].
41 
Scienmag
MAY 13, 2021
Scientists at the Ragon Institute of MGH, MIT and Harvard discover epigenetic changes unique to B cells and B cell subtypes BOSTON – B cells are the immune cells responsible for creating antibodies, and most B cells, known as B2 cells, produce antibodies in response to a pathogen or a vaccine, providing defense and immunity […].
40 
pharmaphorum
JULY 7, 2022
When COVID-19 first emerged, scientists cautioned that developing an effective and safe vaccine could take longer than the commonly estimated figure of a year. Once the pandemic hit, Moderna teamed up with the US National Institute of Allergy and Infectious Diseases (NIAID) to co-develop the former’s vaccine.
104 
Scienmag
FEBRUARY 15, 2021
15, 2021 – By capitalizing on a convergence of chemical, biological and artificial intelligence advances, University of Pittsburgh School of Medicine scientists have developed an unusually fast and efficient method for discovering tiny antibody fragments with big potential for development into therapeutics against deadly diseases.
40 
Scienmag
AUGUST 21, 2020
While antibodies may fade fast, T cells appear to be long-lived and might confer lasting immunity.
Delveinsight
AUGUST 27, 2020
The phase 1 study that is being run by the National Institute of Allergy and Infectious Diseases tests three dose levels of the vaccine, mRNA-1273, given in two injections a month apart in 120 adults. Freenome secures USD 270 Million to boost its colorectal cancer blood test. White fat, in contrast, can build up and cause obesity.
53 
XTalks
JANUARY 20, 2021
However, IBS patients do not have allergies to any given foods, nor any gastrointestinal conditions, such as celiac disease. Through laboratory and clinical studies, the scientists discovered that blockade of histamine could help alleviate IBS symptoms. Moreover, the response did not induce symptoms typical of a food allergy.
The Pharma Data
NOVEMBER 16, 2020
and the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. It combines Moderna’s mRNA (messenger RNA) delivery platform with the stabilized SARS-CoV-2 spike immunogen (S-2P) developed by NIAID scientists. National Institutes of Health to respond to the global pandemic.
Scienmag
AUGUST 11, 2020
Baylor Scott & White Research Institute becomes first site in the world to conduct new trial testing experimental monoclonal antibodies as a treatment for hospitalized COVID-19 patients Credit: Baylor Scott & White Research Institute DALLAS, Texas – On Wednesday, August 5, in Dallas, just one day after the initiative was launched by (..)
The Pharma Data
APRIL 14, 2021
government for its neutralizing antibody therapies authorized for emergency use as a treatment for COVID-19. Lilly’s bamlanivimab was the first neutralizing monoclonal antibody to receive emergency use authorization from the U.S. Eli Lilly and Company (NYSE: LLY) today announced changes to the purchase agreements with the U.S.
52 
The Pharma Data
APRIL 16, 2021
that bamlanivimab alone may not fully neutralize, and with sufficient supply of etesevimab, we believe now is the right time to complete our planned transition and focus on the administration of these two neutralizing antibodies together.” . “With the growing prevalence of variants in the U.S. spanning four continents.
52 
The Pharma Data
MARCH 4, 2021
Dupixent is a fully human monoclonal antibody that inhibits the signaling of the interleukin-4 (IL-4) and interleukin-13 (IL-13) pathways and is not an immunosuppressant. Detailed results from this Phase 3 trial will be published later this year.
52 
The Pharma Data
MARCH 13, 2022
That’s because the mutations that led to the variant’s emergence aren’t found in the regions of the virus that stimulates one type of cellular immune response, says an international research team from Johns Hopkins Medicine, in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID) and ImmunoScape, a U.S.-Singapore
The Pharma Data
FEBRUARY 12, 2022
Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for bebtelovimab, an antibody that demonstrates neutralization against the Omicron variant, Eli Lilly and Company (NYSE: LLY) announced today. “As a global pharmaceutical company, Lilly has worked hard to fight this pandemic. About bebtelovimab.
40 
The Pharma Data
DECEMBER 17, 2020
MacroGenics, a biopharma company working to make cancer history with the development of innovative monoclonal antibody-based therapeutics, had its first product , MARGENZA , approved by the FDA on Wednesday. When Pigs Fly Allergy-friendly. The FDA approval of Klisyri is a significant milestone for Athenex.
52 
The Pharma Data
MARCH 5, 2021
of regulation 726/2004 provides a harmonized, EU-level opinion on the efficacy, quality, and safety of the antibodies. Lilly Antibody Therapies Around the World. Bamlanivimab is a recombinant, neutralizing human IgG1 monoclonal antibody (mAb) directed against the spike protein of SARS-CoV-2.
40 
The Pharma Data
FEBRUARY 19, 2022
Dupixent is a fully human monoclonal antibody that inhibits the signaling of the interleukin-4 (IL-4) and interleukin-13 (IL-13) pathways and is not an immunosuppressant. About Dupixent. Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents life-transforming medicines for people with serious diseases.
40 
The Pharma Data
FEBRUARY 13, 2022
About Dupixent Dupixent is a fully human monoclonal antibody that inhibits the signaling of the interleukin-4 (IL-4) and interleukin-13 (IL-13) pathways and is not an immunosuppressant. In 2016, the FDA granted Breakthrough Therapy designation for Dupixent for the treatment of severe atopic dermatitis (in children aged 6 months to 11 years).
40 
The Pharma Data
APRIL 4, 2022
Dupixent is a fully human monoclonal antibody that inhibits the signaling of the interleukin-4 (IL-4) and interleukin-13 (IL-13) pathways and is not an immunosuppressant. There are approximately 160,000 patients in the U.S. living with EoE who are currently treated, of whom approximately 48,000 have failed multiple treatments. About Dupixent.
52 
The Pharma Data
MARCH 11, 2021
In this data set, the safety profile of bamlanivimab and etesevimab together was consistent with observations from other Phase 1, Phase 2 and Phase 3 trials evaluating these antibodies. Bamlanivimab is a recombinant, neutralizing human IgG1 monoclonal antibody (mAb) directed against the spike protein of SARS-CoV-2.
40 
The Pharma Data
MAY 4, 2021
Monoclonal antibodies, such as bamlanivimab and etesevimab, may be associated with worse clinical outcomes when administered to hospitalized patients with COVID-19 requiring high flow oxygen or mechanical ventilation. Point mutations were introduced into the native human IgG1 antibody to mitigate effector function.
52 
XTalks
AUGUST 2, 2023
2) Darzalex (daratumumab) Darzalex is a targeted monoclonal antibody that slows or stops the progression of multiple myeloma (a blood cancer) by binding to the CD38 protein on multiple myeloma cells. The monoclonal antibody targets CD20, a protein found on the surface of B lymphocytes (B cells). billion in 2022, a 32.44
98 
The Pharma Data
AUGUST 30, 2021
Dupixent is a fully human monoclonal antibody that inhibits the signaling of the interleukin-4 (IL-4) and interleukin-13 (IL-13) pathways. It is not an immunosuppressant and does not require lab monitoring. Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents life-transforming medicines for people with serious diseases.
52 
XTalks
DECEMBER 7, 2020
Then came news from the Massachusetts-based biotech firm Moderna which announced that its vaccine — also an mRNA vaccine created at the National Institute of Allergy and Infectious Diseases’ vaccine research center — was strongly protective against the SARS-CoV-2 virus as well. New Treatments for COVID-19. Update: November 9, 2020.
52 
pharmaphorum
JULY 26, 2022
AIDS was first identified in the US in 1981, but four decades later scientists are still learning exactly how the virus that causes the condition is structured and how the body reacts, or fails to react, once infected. Understanding the virus. The finding opens up the possibility of creating therapeutics that mimic the same response.
140 
XTalks
DECEMBER 24, 2020
After being identified in December 2019 in Wuhan, Hubei in China, medical officials and scientists got to work to isolate and identify the novel virus that they observed to be causing a new respiratory illness. Most antibody drugs and vaccines have been developed to target parts of the spike protein. Drug Approvals.
111
Expert insights. Personalized for you.
We have resent the email to
Are you sure you want to cancel your subscriptions?
Let's personalize your content